Regeneron Pharmaceuticals reported fourth quarter 2025 total revenue of $3.9 billion, up 3% year-over-year, driven by double-digit growth in key products Dupixent (+32% YoY to $4.9B) and Eylea HD (+66% YoY to $506M), which offset a 15% sequential decline in Eylea 2mg sales. Full-year Dupixent global sales reached $17.8 billion, solidifying its status as a market leader. The company generated $4.1 billion in free cash flow and returned $3.8 billion to shareholders through buybacks and dividends, while announcing a new quarterly dividend of $0.94. Looking ahead to 2026, management raised R&D guidance to $5.9-$6.1 billion to support 18 new Phase III studies and highlighted upcoming catalysts including the Libtayo/fianlimab melanoma readout and the submission of a long-acting Dupixent candidate.
| Metric | Value | Change |
|---|---|---|
| Total Revenue | $3.9 billion | +3% YoY |
| Dupixent Global Sales | $4.9 billion | +32% YoY (CC) |
| Eylea HD US Sales | $506 million | +66% YoY |
| Eylea 2mg US Sales | $577 million | -15% QoQ |
| EPS (Diluted) | $11.44 | N/A |
| Free Cash Flow | $4.1 billion | Full Year 2025 |
| Share Repurchases | $3.4 billion | Full Year 2025 |
Regeneron is executing a 'Trojan horse' strategy in obesity by combining its licensed GLP-1/GIP agonist (olororepiti) with Praluent (PCSK9 inhibitor). Management emphasized that while many competitors are fighting over marginal weight loss differences, their co-formulation targets the large subset of obese patients with high cholesterol, offering 50-60% LDL reduction alongside weight loss. This leverages their existing antibody formulation capabilities to create a differentiated product that could be prescribed to every obese patient regardless of lipid status.
The company is aggressively extending the Dupixent franchise through next-generation 'long-acting' antibodies. Management revealed a 'souped-up' version of Dupixent (a naturally selected variant with potentially better properties) and bispecifics targeting IL-13 and IL-4/13. This strategy aims to maintain dominance in the Type II inflammatory space beyond the current patent lifecycle, utilizing their VelocImmune technology to create assets that competitors cannot easily replicate.
Eylea HD is successfully mitigating the decline of the original Eylea franchise. With sales up 66% year-over-year and now representing nearly half of Regeneron's total anti-VEGF sales, the high-dose formulation is driving growth despite a 7% sequential decline in the overall anti-VEGF category. The upcoming FDA decision on the prefilled syringe (expected late April) and recent label expansions for monthly dosing and RVO are expected to further accelerate adoption and protect against 2026 biosimilar competition for Eylea 2mg.
Regeneron is positioning linvoseltamab (BCMAxCD3) as a potential paradigm shift in multiple myeloma treatment. Management highlighted unprecedented data showing 100% MRD negativity in smoldering myeloma and rapid light chain normalization compared to standard quad combos. The strategy involves moving this asset into earlier lines of therapy and monotherapy settings, aiming to simplify the complex, toxic current treatment paradigms with a high-efficacy, convenient bispecific antibody.
The company is diversifying into anticoagulation with two complementary Factor XI antibodies optimized for maximal antithrombotic activity or reduced bleeding. This addresses a critical unmet need for patients who discontinue current anticoagulants due to bleeding risks. With pivotal studies initiating in 2026 for stroke prevention and VTE, this represents a significant market expansion opportunity leveraging their antibody engineering capabilities.
The original Eylea (2mg) franchise is eroding rapidly ahead of the 2026 biosimilar launch. US net sales for Eylea 2mg declined 15% sequentially in Q4, and management explicitly warned that competitive pressure 'will intensify' in 2026. While Eylea HD is growing, the overall anti-VEGF category grew only 5% in 2025, and the branded segment declined 12%, indicating a tough market environment where Eylea HD must steal share from both its older sibling and Roche/Novartis to sustain growth.
Elevated wholesaler inventory levels created a $30 million headwind that will negatively impact Q1 2026 financial results. Management noted that Q1 is typically impacted by patient reauthorizations, and the inventory drawdown adds a layer of complexity to the near-term revenue trajectory for the ophthalmology franchise.
Research and development expenses are rising significantly, with 2026 guidance set at $5.9-$6.1 billion, up from 2025 levels. This increased spend is necessary to support 18 new Phase III studies and early-stage programs, but it pressures operating margins. The company is betting heavily on assets like the GLP-1/GIP combo and Factor XI antibodies, which are entering crowded or highly competitive therapeutic areas.
Gross margin guidance for 2026 (83-84%) suggests potential margin compression compared to historical performance. Management attributes this to a changing product mix (likely growth of lower-margin collaboration revenue vs. high-margin Eylea solo sales) and costs associated with expanding bulk manufacturing capacity. This indicates that scaling the new pipeline may come at a near-term cost to profitability.
Overall: Management exhibited a highly confident and assertive tone throughout the call, particularly regarding the strength of their scientific pipeline and their ability to differentiate from 'me-too' competitors. Dr. Schleifer was defensive and emphatic about Dupixent's safety profile compared to emerging JAK and OX40 inhibitors, while Dr. Yancopoulos displayed enthusiasm about the breadth of the pipeline, describing it as having 'never been more excited.' The tone shifted from commercial execution in the prepared remarks to scientific defensiveness and strategic vision during the Q&A.
Confidence: HIGH - Management provided specific guidance ranges, detailed clinical timelines, and used strong, definitive language when discussing the competitive advantages of their pipeline (e.g., 'Trojan horse,' 'best-in-class'). They dismissed concerns about Eylea biosimilars by focusing on Eylea HD growth and pipeline diversification.
$5.9 billion - $6.1 billion
$2.5 billion - $2.65 billion
83% - 84%
$1.1 billion - $1.3 billion
13% - 15%
Hedging & Uncertainty: Management generally used direct language regarding past performance but employed specific temporal hedges regarding future regulatory milestones. Phrases like 'decision... is expected in late April' and 'we anticipate reaching agreement' were used to set timelines without guaranteeing outcomes. However, confidence was high regarding clinical data, with minimal hedging on efficacy statements (e.g., 'linvoseltamab... demonstrated nearly double the complete response rate'). Notably, management used 'we believe' and 'potential' frequently when discussing competitive differentiation in obesity and GA, acknowledging the risk of these unvalidated markets.
"Trojan horse... Imagine. They just wanna lose their weight. And they're not even gonna realize that they're gonna be helping their hearts." - George Yancopoulos, President and CSO
"Souped-up version of Dupixent... might have even more improved properties." - Leonard Schleifer, CEO
"Vestigial part of the immune system... largely ever inactivated in our modern world." - Leonard Schleifer, CEO
"Disappointed with the industry... trying to come up with a me too." - George Yancopoulos, President and CSO
"We anticipate at least four FDA approvals... setting the foundation for Regeneron's next wave of potential blockbuster products." - Leonard Schleifer, CEO
Analyst Sentiment: Analysts focused heavily on the competitive landscape, specifically asking for details on the upcoming Libtayo melanoma readout, the durability of Dupixent IP in light of Sanofi's comments, and the differentiation strategy for the obesity program given market saturation. There was skepticism about the ability to compete in obesity without a clear 'best-in-class' weight loss profile.
Management Responses: Management deflected specific IP questions but pivoted aggressively to the strength of their pipeline follow-ons (long-acting Dupixent). They were very responsive on obesity, reframing the narrative from weight loss efficacy to cardiovascular benefit (LDL lowering) via the PCSK9 combo. They appeared eager to discuss the science of their pipeline, particularly the mechanism of action for their C5 and Factor XI inhibitors.
Libtayo/Fianlimab Melanoma Data: Analysts sought clarity on the timing of the H1 readout and the hazard ratio bar. Management confirmed the study is powered for PFS and OS benefit but offered no specific date.
Dupixent IP Lifecycle: Following Sanofi's comments on extending the runway, management emphasized their internal 'souped-up' Dupixent and bispecifics as the primary drivers of long-term value.
Obesity Strategy Differentiation: Management argued that their GLP-1/GIP + PCSK9 combo is a 'Trojan horse' to treat cardiovascular disease, differentiating them from pure-play weight loss drugs.
Geographic Atrophy (GA) Market: Analysts questioned the market potential given slow uptake of current drugs. Management argued their systemic C5 approach avoids the safety risks (blindness) of current intravitreal therapies.
Regeneron is successfully transitioning from a reliance on Eylea to a diversified, high-growth platform driven by Dupixent and a deep late-stage pipeline. The 32% growth in Dupixent and 66% surge in Eylea HD demonstrate commercial resilience despite biosimilar headwinds. We view the obesity/PCSK9 combination as a highly differentiated 'Trojan horse' strategy that bypasses the commoditization of GLP-1 therapies. Furthermore, the linvoseltamab data in myeloma and the upcoming Libtayo readouts in melanoma provide near-term catalysts. While R&D spend is rising, the deployment of capital into 18 new Phase III studies and the initiation of a dividend signal strong confidence in long-term cash generation. The risk of Eylea 2mg erosion is priced in, but the pipeline upside is not.
Management noted 'patient co-pay affordability issues' dampening anti-VEGF growth and is actively negotiating with CMS regarding drug pricing. They anticipate reaching an agreement within frameworks established by peers, suggesting a managed but pressured pricing environment.
The anti-VEGF market is experiencing 'intensifying' pressure from biosimilars expected in 2026, and the overall branded category declined 12% in 2025. Management is navigating this by shifting share to Eylea HD.
The FDA approval of Eylea HD for monthly dosing and RVO, along with the acceptance of the prefilled syringe filing, indicates a smoother regulatory path for key ophthalmology assets compared to previous manufacturing hurdles.